Amgen, Astellas to develop cancer, bone treatments in Japan

AMGEN INC. and Japan-based Astellas Pharma Inc. have partnered to create a venture called Amgen Astellas BioPharma KK, which will become an Amgen subsidiary as early as 2020.  / BLOOMBERG FILE PHOTO
AMGEN INC. and Japan-based Astellas Pharma Inc. have partnered to create a venture called Amgen Astellas BioPharma KK, which will become an Amgen subsidiary as early as 2020. / BLOOMBERG FILE PHOTO
WASHINGTON - Amgen Inc., one of the world’s largest biotechnology companies by sales, announced a partnership with Japanese drugmaker Astellas Pharma Inc. to bring five of its experimental therapies to market in that country. The companies will create a venture called Amgen Astellas BioPharma KK that will become an Amgen subsidiary as early as 2020,…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -

No posts to display